Kiniksa Pharmaceuticals International Plc. P/E Ratio

Kiniksa Pharmaceuticals International Plc. (KNSA) currently reports a P/E ratio of 72.19. That is above the Healthcare sector average of 25.3. Use the charts on this page to explore Kiniksa Pharmaceuticals International Plc.'s P/E ratio history and peer comparisons.

Kiniksa Pharmaceuticals International Plc.'s P/E ratio of 72.19 is higher than the Healthcare sector average of 25.3. That is roughly 185.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Kiniksa Pharmaceuticals International Plc.'s market price to a fundamental measure such as earnings, sales, or book value. At 72.19, KNSA can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 72.19, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.3. From there, open related valuation or income-statement pages for Kiniksa Pharmaceuticals International Plc., and consider following KNSA for alerts when major investors trade the stock.

Kiniksa Pharmaceuticals International Plc. is classified in the Healthcare sector. On P/E ratio, it currently shows 72.19 versus a sector average near 25.3. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KNSA with unrelated industries.